Company Overview:
Zai Lab
ZLAB , a leading Chinese biotech firm, is on track for non-GAAP profitability by Q4 2025, driven by strong revenue growth & cost management.
Key Catalysts:
Financial Discipline & Expansion 💰
Operating losses fell 45% in Q4 2024, highlighting cost efficiency while scaling operations.
Analysts project $2 billion in annual revenue by 2028, reinforcing long-term value creation.
Blockbuster Drug Pipeline 💊
VYVGART generated $93.6M in its first full launch year, demonstrating strong adoption.
KarXT & bemarituzumab are key upcoming growth drivers, expanding ZLAB’s market footprint.
Investment Outlook:
Bullish Case: We are bullish on ZLAB above $34.00-$35.00, supported by financial execution & product expansion.
Upside Potential: Our price target is $54.00-$55.00, driven by strong product adoption & long-term growth trajectory.
🔥 Zai Lab – Unlocking the Future of Biotech Innovation. #ZLAB #Biotech #GrowthStocks
Zai Lab
ZLAB , a leading Chinese biotech firm, is on track for non-GAAP profitability by Q4 2025, driven by strong revenue growth & cost management.Key Catalysts:
Financial Discipline & Expansion 💰
Operating losses fell 45% in Q4 2024, highlighting cost efficiency while scaling operations.
Analysts project $2 billion in annual revenue by 2028, reinforcing long-term value creation.
Blockbuster Drug Pipeline 💊
VYVGART generated $93.6M in its first full launch year, demonstrating strong adoption.
KarXT & bemarituzumab are key upcoming growth drivers, expanding ZLAB’s market footprint.
Investment Outlook:
Bullish Case: We are bullish on ZLAB above $34.00-$35.00, supported by financial execution & product expansion.
Upside Potential: Our price target is $54.00-$55.00, driven by strong product adoption & long-term growth trajectory.
🔥 Zai Lab – Unlocking the Future of Biotech Innovation. #ZLAB #Biotech #GrowthStocks
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.